RESUMEN
ImportanceEvidence suggests that early, robust type 1 interferon responses to SARS-CoV-2 are critical determinants for COVID-19 disease outcomes, accelerating viral clearance and limiting viral shedding. ObjectiveWe undertook a ring prophylaxis study to determine whether pegylated IFN{beta}-1 could reduce SARS-CoV-2 household transmission. DesignA cluster randomized clinical trial of pegylated IFN{beta}-1 conducted in Santiago, Chile. Recruitment was conducted between December 4th 2020, and 31st May 2021, with the last follow-up completed June 29th 2021. SettingThe study was conducted across 341 households in the metropolitan area of Santiago, Chile. ParticipantsIndex cases were identified from databases of those with confirmed SARS-CoV-2 from COVID-19 clinics and emergency room visits in Santiago, Chile. 5,154 index cases were assessed for eligibility, 1,372 index cases were invited to participate, and 341 index cases and their household contacts (n = 831) were enrolled in the study. InterventionHouseholds were cluster randomized to receive 125{micro}g subcutaneous pegylated IFN{beta}-1 (n = 172 households, 607 participants), or standard care (n = 169 households, 565 participants). Main Outcome(s) and Measure(s)Frequentist and Bayesian analyses were undertaken to determine the effects of treatment on (i) reducing viral shedding in index cases and (ii) reducing viral transmission to treatment-eligible household contacts. Four secondary outcomes were assessed including duration of viral shedding, effects on viral transmission and seroconversion, incidence of hospitalization, and incidence and severity of reported adverse events. A post-hoc at risk population was defined as households where the index case was positive at the start of the study and there was at least one treatment eligible contact in a household who tested negative for SARS-CoV-2. ResultsIn total, 1172 participants in 341 households underwent randomization, with 607 assigned to receive IFN{beta}-1 and 565 to standard care. Based on intention to treat and per protocol analyses, IFN{beta}-1 treatment was ineffective. However, in the at risk population, the relative risk of infection was reduced by 23% in treated individuals and that there was a 95% probability that IFN{beta}-1 reduced household transmission Conclusions and RelevanceRing prophylaxis with IFN{beta}-1 reduces the probability of SARS-CoV-2 transmission within a household. Trial RegistrationClinicaltrials.gov identifier: NCT04552379
RESUMEN
BackgroundThe global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon-2b in a cohort of confirmed COVID-19 cases in Wuhan, China. MethodsIn this retrospective study, 77 adults hospitalized with confirmed COVID-19 were treated with either nebulized IFN-2b (5mU b.i.d.), arbidol (200mg t.i.d.) or a combination of IFN-2b plus arbidol. Serial SARS-CoV-2 testing along with hematological measurements, including cell counts and blood biochemistry, serum cytokine levels, temperature and blood oxygen saturation levels were recorded for each patient during their hospital stay. ResultsTreatment with IFN-2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP. ConclusionThese findings suggest that IFN-2b should be further investigated as a therapy in COVID-19 cases.
